Olaparib Improves Outcomes in BRCA-Mutated Metastatic Breast Cancer

The PARP inhibitor olaparib increases progression-free survival and improves quality of life in BRCA-mutated HER2-negative metastatic breast cancer patients.

Source: CancerNetwork - June 4, 2017 Category: Cancer & Oncology Authors: Mark Fuerst Tags: Conferences/ASCO Breast Cancer News Source Type: news